Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent.
Background: Mycophenolate mofetil (MMF) has enjoyed increasing popularity as an emerging immunosuppressant treatment for various autoimmune dermatologic conditions, including pyoderma gangrenosum (PG).Objective: The aim of this study was to examine the efficacy and safety of MMF as used in PG.Method...
| Publicado en: | Journal of the American Academy of Dermatology Vol. 69; no. 4; pp. 565 - 570 |
|---|---|
| Autores principales: | , |
| Formato: | research Journal Article |
| Publicado: |
Elsevier B.V.
Oct2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109861079&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 109861079 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01909622 1ZF jtl: Journal of the American Academy of Dermatology issn: 01909622 maglogo: N pubinfo: dt: Oct2013 vid: 69 iid: 4 pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 109861079 NLM23850090 2012297229 10.1016/j.jaad.2013.05.028 NLM23850090 109861079 ppf: 565 ppct: 5 formats: tig: atl: Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. aug: au: Li, Jane Kelly, Robert affil: Department of Dermatology, St Vincent's Hospital Melbourne, Victoria, Australia. Electronic address: jane.melb@gmail.com. sug: subj: Antiinflammatory Agents, Non-Steroidal Therapeutic Use Mycophenolic Acid Pyoderma Gangrenosum Diagnosis Pyoderma Gangrenosum Drug Therapy Wound Healing Drug Effects Adult Aged Aged, 80 and Over Prospective Studies Dose-Response Relationship, Drug Drug Administration Schedule Female Hospitalization Statistics and Numerical Data Human Male Middle Age Mycophenolic Acid Adverse Effects Mycophenolic Acid Therapeutic Use Pyoderma Gangrenosum Epidemiology Retrospective Design Risk Assessment Severity of Illness Indices Treatment Outcomes Victoria Young Adult Adult: 19-44 years Aged: 65+ years Aged, 80 & over Middle Aged: 45-64 years Female Male ab: Background: Mycophenolate mofetil (MMF) has enjoyed increasing popularity as an emerging immunosuppressant treatment for various autoimmune dermatologic conditions, including pyoderma gangrenosum (PG).Objective: The aim of this study was to examine the efficacy and safety of MMF as used in PG.Methods: A retrospective chart review was conducted for all patients with PG treated with MMF at our institution (Victoria, Australia) for the past 11 years (2001-2012).Results: We identified 26 patients, 14 female and 12 male. Nine patients (34.6%) had associated systemic conditions. All patients received prednisolone. MMF was used as a first-line steroid-sparing agent in 11 patients (42.3%), second-line in 14 (53.8%), and third-line in 1 (3.85%). The average duration of treatment was 12.1 months. Fourteen patients experienced side effects (53.8%), although most were mild (26.9%). One patient died after a sigmoid colon perforation (3.85%). Overall 22 patients demonstrated clinical improvement during MMF treatment (84.6%). Thirteen patients achieved complete ulcer healing (50%), 10 while taking MMF and 3 after ceasing it.Limitations: This is a retrospective study based on a single-center cohort.Conclusion: Our experience suggests that MMF is highly efficacious in PG together with prednisolone, or as part of combination therapy with other immunosuppressants. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|